Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, 58 Zhongshan Road 2, Guangzhou, 510080, China.
BMC Med Imaging. 2023 Dec 6;23(1):202. doi: 10.1186/s12880-023-01159-3.
To summarize our single-center experience with percutaneous ultrasound (US)-guided radiofrequency ablation (RFA) for pediatric recurrent hepatocellular carcinoma (RHCC).
From September 2007 to September 2021, patients under 18 who underwent percutaneous US-guided RFA for RHCC were retrospectively enrolled in this study. Local effectiveness, complications, local tumor progression (LTP), progression free survival (PFS), and overall survival (OS) were evaluated.
A total of 10 patients (9 male and 1 female; mean age, 11.7 ± 4 years ; age range, 6-17 years) with 15 intrahepatic RHCC lesions were enrolled in this study. Complete ablation (CA) was achieved in 14 out of 15 lesions (93.3%) after the first RFA. During the follow-up (mean, 63.1 ± 18 months; range, 5.3-123.3 months), LTP did not occur. Five patients died including three with tumor progression and one with liver failure. The accumulative one- and three-year PFS rates were 30% and 10%, respectively. The accumulative one- and three-year OS rates were 77.8% and 44.4%, respectively.
Our single-center experience suggests the safety and feasibility of percutaneous US-guided RFA for pediatric RHCC.
总结我们单中心经皮超声(US)引导射频消融(RFA)治疗小儿复发性肝细胞癌(RHCC)的经验。
本研究回顾性纳入 2007 年 9 月至 2021 年 9 月期间在我院接受经皮 US 引导 RFA 治疗 RHCC 的 18 岁以下患者。评估局部疗效、并发症、局部肿瘤进展(LTP)、无进展生存期(PFS)和总生存期(OS)。
本研究共纳入 10 例(9 男 1 女;平均年龄 11.7±4 岁;年龄范围 6-17 岁)15 个肝内 RHCC 病灶。15 个病灶中 14 个(93.3%)在首次 RFA 后达到完全消融(CA)。在随访期间(平均 63.1±18 个月;范围 5.3-123.3 个月),未发生 LTP。5 例患者死亡,包括 3 例肿瘤进展和 1 例肝功能衰竭。累积 1 年和 3 年的 PFS 率分别为 30%和 10%。累积 1 年和 3 年的 OS 率分别为 77.8%和 44.4%。
我们的单中心经验表明,经皮 US 引导 RFA 治疗小儿 RHCC 是安全可行的。